Drug · DIN 02239195
LYMERIX
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since July 31, 2002; first marketed April 19, 1999.
- Drug Identification Number (DIN)
- 02239195
- Company (DIN owner)
- Glaxosmithkline IncMississauga, Ontario, Canada
- Schedule
- Schedule d
- Dosage form
- Liquid
- Route
- Intramuscular
- Therapeutic class (ATC)
- Other bacterial vaccines J07AX
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| LIPOPROTEIN - OSPA ANTIGEN RECOMBINANT | 30 MCG | 0.5 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- July 20, 2001: NOC 2371New Drug Submission (NDS) · Change in manufacturer name
- December 2, 1998: NOC 3015New Drug Submission (NDS)